Attend
15th Biosimilars & Biologics World Congress 2025 Europe
Strategies, Innovations and Collaborations for Sustainable Biosimilars
London, United Kingdom
Thursday 4th - Friday 5th September 2025
We are delighted to invite you to our 15th Biosimilars & Biologics Global Congress 2025. This annual event serves as a premier forum, bringing together influential individuals and pioneering thinkers from the biosimilar and pharmaceutical sectors. Our attendees include industry leaders, policy makers, regulatory experts, patient advocates, and healthcare professionals, all dedicated to expanding patient access and promoting the progress of biosimilar & biologic medicines within the wider healthcare frame work.
The growing importance of biological therapies is clear, offering significant health benefits while also posing considerable challenges related to healthcare funding, organizational frameworks, infrastructure, and global supply networks. Recognizing these evolving dynamics, effective biosimilar policies have become essential, delivering substantial value to the entire healthcare community by enabling broader access to these critical treatments.
This year’s Congress is structured as an engaging platform for comprehensive discussions on the most significant issues influencing the future of biosimilars. We will explore vital topics such as improving patient access to biotherapies, encouraging robust market competition, understanding the newest developments in regulatory science, and examining the transformative impact of biosimilar medicines on healthcare systems and the supporting industrial landscape.
We believe that the 15th Biosimilars and Biologics Global Congress 2025 will offer a valuable opportunity for knowledge acquisition, professional networking, and collaborative solutions. We eagerly anticipate your active participation in these crucial discussions, which will undoubtedly contribute to the ongoing advancement of biosimilar & biologic medicines and better outcomes for patients. We would be honoured to have you join us at the Congress.
We look forward to meeting you at the Congress!
Sincerely,
Jocelyn Raguindin – Conference Director
Facilitate Live
Who Should attend:
This Conference is designed for Chief Executives, Executive Directors, VicePresidents, Heads and Team Leaders and Managers working within:
Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:
- Follow on Biologics/Biosimilar
- Biologics/Biotechnology/ Biogenerics
Biopharmaceuticals/Biotherapeutics - Legal Affairs
- Pricing and Reimbursement
- Clinical Immunology
- Regulatory Compliance
- Research & Development
- Preclinical and Clinical Development
- New Product Development
- Quality Affairs/ Quality Control
- Principal Scientist
- Pharmacovigilance
- Chief Scientific Officer
- Drug Safety & Risk Management
- Process Control and Analytical Technologies
- Business Development
- Commercial Affairs
- Marketing & sales
- Intellectual Property
- Legislation and Policy Advice
- Business Development
- Licensing
- Manufacturing
- Bioequivalence
- Drug and Safety Assessment
- Market Strategy
- Regulatory Affairs
- Health Economics
Gain The Latest Insights On:
- Focusing on achieving a balanced regulatory environment and fostering healthy
market competition within the biosimilar space. - Addressing the critical interplay between short-term market dynamics and longer-
term healthcare objectives. - Key enablers and successful strategies that have proven effective in expanding access to essential biotherapies.
- Analytical tools can be leveraged to identify inefficiencies and access gaps, thereby informing more strategic healthcare investments.
- Streamlining the development pathway for biosimilars can further stimulate
competition across a wider spectrum of biological medicines. - Impact of horizon scanning on the priorities of payers and regulatory agencies.
- Invaluable contributions of patients and healthcare professionals in driving the
adoption of biosimilars across new and expanding therapy areas. - Priority actions needed to pave the way for the introduction of Advanced Therapies biosimilars to the European market.
- Analyzing the global biotech ecosystem as it relates to biosimilar research and
development, as well as manufacturing capabilities, with a specific focus on Europe’s competitive standing in this international landscape.



Delegate Tickets
Group Discounts Are Also Available
Early Bird Discount
Pharma /Biotech- Full Access - 2 Day Conference
- All Day Refreshments & Lunches
- Conference Documentations
Standard Registration Rate
Pharma / Biotech- Full Access - 2 Day Conference
- All Day Refreshments & Lunches
- Conference Documentations